TrialAnnals of the rheumatic diseases2017

Canakinumab reverses overexpression of inflammatory response genes in tumour necrosis factor receptor-associated periodic syndrome.

Rebecca Torene et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.